"The panel urges clinicians to consider the pretest probability of AD pathology for each patient when deciding whether or not to use a BBM test,” and not as a standalone diagnostic tool.
Neuroimaging detects reduced grey matter in multiple brain regions among breast cancer patients after chemotherapy, raising concern for long-term cognitive risks.